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Background: Adverse drug events could often be prevented. One of their main causes is that patients rarely know
how to detect them. Another cause is inadequate communication between patients and physicians. If patients
were to be effectively trained in detecting and reporting adverse drug events, this should help to prevent their
occurrence and subsequent complications. Our purpose is to present the protocol of the InPAct trial, which aims to
evaluate an interactive program that encourages patients to report adverse drug events in primary care.
Methods/design: We will conduct a cluster randomised controlled stepped wedge trial, with eight clusters of 10
general practitioners each. The physicians will suggest to all of their antihypertensive-treated patients that they take
part in this study. The InPAct program will be implemented in the clusters in random order along five successive
three-month periods. Two new clusters will be trained in implementing the program at each step. The program
features: an interactive patient booklet including informative paragraphs, several care plans and adverse drug event
report forms; and standardised training of physicians in how to present the booklet to the patient. The primary
outcome will be the reporting of adverse drug events by patients to their physician within three months. We
assume that the number of patients reporting at least one adverse drug event will increase from 3% before
program implementation to 7.5% afterward (coefficient of variation = 0.5, α = 0.05, β = 0.2), which means that 1,200
patients must be included. The effect of the intervention on the main outcome will be quantified and tested using
a mixed logistic model to integrate cluster and time effects.
Discussion: Our choice of a stepped wedge design is particularly appropriate for evaluating the implementation of
a patient safety program within the constraints of general practice. We describe the InPAct intervention, which is an
original program that is intended to improve communication between patients and physicians. Indeed, none of the
previously published intervention studies has combined a patient education program and a patient reporting
system for adverse drug events with the aim of improving patient safety in primary care.
Trial registration: This study is registered in ClinicalTrials.gov NCT01610817.
Keywords: Patient safety intervention, Primary health care, Antihypertensive drug, Adverse drug event, Cluster
randomised controlled trial, Stepped wedge* Correspondence: maud.kerielg@free.fr
1Université de Lyon, Lyon F-69000, France
2Université Lyon 1, Département de Médecine Générale, Lyon F-69373,
France
Full list of author information is available at the end of the article
© 2013 Keriel-Gascou et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Keriel-Gascou et al. Implementation Science 2013, 8:69 Page 2 of 8
http://www.implementationscience.com/content/8/1/69Background
According to a recent report of the Canadian Patient
Safety Institute, the management of adverse drug events
(ADEs) in primary medical care is a public health prior-
ity [1]. The proportion of patients presenting an ADE
within the first three months following an ambulatory
drug prescription was estimated to reach 25% in Gandhi
et al. [2]. Cardiovascular drugs have been found respon-
sible for 20% to 30% of hospitalisations for ADEs; mean-
while, 20% to 40% of ADEs could be prevented [2,3]. A
lack of information and communication between pa-
tients and health care professionals has been identified
as an underlying factor favouring the occurrence of
ADEs [4,5]. A significant proportion of ADEs and asso-
ciated complications could be prevented if risk situations
were detected earlier and if patients were better in-
formed about participating in their own medical care
and about reporting ADEs [6]. In the InPAct (Informa-
tion for Participating Actively) study, we focused on the
reporting of ADEs by patients. Because clear differences
have been shown between reports emanating from pa-
tients and those emanating from health professionals, it
is essential that patients be able to report ADEs in order
to supplement the reporting of ADEs by health profes-
sionals [7,8]. It has been found that patients report
ADEs four times less often than do health professionals
[7,9]. Considerable variations have been observed from
one country to another in terms of the proportion of
total ADE reports submitted by patients as opposed to
the proportion submitted by health professionals [10]. In
France, according to data from the ANSM (French Na-
tional Agency for the Safety of Medicines and Health
Products), only 1% of official ADE reports are made by a
patient. We decided to focus on ADE reports made by
antihypertensive-treated patients in primary care for
three reasons. First of all, hypertension is common, with
two-thirds of people older than 65 affected by this con-
dition in developed countries [11]. Also, drug prescrip-
tions for this sector of the population are often
composed of at least four different drugs, which in-
creases the risk of ADEs [12-14]. Finally, the proportion
of patients experiencing at least one ADE within the first
three months following the prescription of an antihyper-
tensive has been estimated at 12.6% [2].
The InPAct intervention is an interactive program. It
consists of educating patients about taking a more active
role in their own care, so that they are more likely to re-
port antihypertensive-related ADEs to their general
practitioner (GP). Another important goal of the InPAct
program is to improve patient safety in primary care.
Our purpose is to present the methodology and
expected results of the InPAct trial. The primary out-
come aims to evaluate the effectiveness of the InPAct
program in promoting patient reports of ADEs. Thesecondary outcomes include the measurement of the
InPAct program’s effectiveness in limiting ADE risk situ-
ations and in reducing the occurrence and severity of
ADEs. The other secondary outcomes are the evaluation
of the health knowledge and the level of satisfaction of
antihypertensive patients with respect to the medical
care provided by their GP.
Methods/design
Study design
The design of the InPAct protocol is a cluster
randomised controlled (CRCT) stepped wedge trial de-
sign, which is appropriate for assessing the impact of pa-
tient safety interventions [15]. This design involves the
sequential rollout of an intervention in the clusters over
several time periods. The order in which the clusters will
receive the intervention is determined at random, and
by the end of the study, all clusters will have received
the intervention. Finally, each cluster will successively be
situated in a control group and then in an intervention
group.
In the InPAct protocol, eight clusters of several GPs
were defined. Four steps, one unit (U) of two clusters
per step, and five periods (from P1 to P5) of three-
month duration were defined. In the first period, the
InPAct program will not be implemented. The InPAct
program will be rolled out sequentially to the four GP
cluster units over the last four time periods (Figure 1).
The order in which the clusters will take part in the pro-
gram is determined at random, allowing the full imple-
mentation of the intervention by all participating GPs by
the end of the trial [16,17].
Setting
The InPAct program will take place in general practi-
tioners’ offices of several suburban cities in three French
regions (Rhône–Alpes, Auvergne and Ile-de-France).
Recruitment of general practitioners
Eight clusters were defined, with ten GP volunteers per
cluster. The GPs were grouped in a cluster according to
criteria of geographic proximity, practice in the same
medical centre, or interaction among professionals.
Recruitment of patient participants
GP investigators involved in the study are required to
recommend participation in this study to each patient
over 18 years old who is consulting to initiate, modify or
renew an antihypertensive drug prescription. In order to
be included, the patients must meet the inclusion cri-
teria, understand the investigator’s language, and agree
to answer a telephone survey at home. Only the patients
included in the study after the entry of their GP into the
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Figure 1 InPAct study design. One unit of randomisation (U1, U2…) contains two clusters of general practitioners, who implement the InPAct
program during the same period of time (P2 to P5). Non-gray cells represent control units. Gray cells represent units in which the InPAct program
was implemented.
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the outcome criteria collected at the end of this period.
InPAct program
The InPAct program consists of providing an inter-
active booklet to the patients as well as standardised
training to the GPs regarding the presentation of the
booklet to the patient. A pilot study involving a small
sample of patients and GPs has already made it pos-
sible to test the feasibility and acceptability of InPAct
program implementation. This pilot study has pro-
vided some arguments in favour of a beneficial effect
of the intervention [18].
1. InPAct booklet description
Ten steps were necessary to develop the InPAct inter-
active booklet [18]. This work was performed by a col-
laborative group including patients, GPs and other
health professionals involved in ambulatory care or who
specialised in one of the medical domains of the study.
The initial booklet was created using the Delphi consen-
sus method [19]. In a following step, a qualitative study
made it possible to improve booklet content and booklet
presentation instructions for GPs. Several tests of text
readability and booklet reviews by communications pro-
fessionals were repeated during the booklet creation
process. The booklet was printed on both sides of a thick,
film-coated, glossy A4-size paper folded into thirds. The
title and instructions for use are on the outside. Inform-
ative paragraphs on hypertension, cardiovascular riskfactors, situations involving a risk of ADEs and a list of
the most frequent antihypertensive-associated ADEs are
inside. Several ADE report forms and several care plans
that can be annotated by the patient are included in the
form of memo pads placed within the booklet.
2. General practitioner training
GP investigators will receive booklets and will participate
in a web seminar explaining the kind of oral information
to provide when the booklet is given to the patient. As
determined by the pilot study, physicians are encouraged
to give the booklet to the patient and to first present the
principal value of the booklet for the patient, that is, the
reporting of ADEs for increased patient safety [18]. In
order to increase physician-patient interaction and com-
munication, physicians are encouraged to first ask sev-
eral questions to evaluate patient knowledge of the
benefits and risks of the antihypertensive drug prescrip-
tion, and to then give some complementary information.
GPs are asked to present the care plan to the patient
and to explain the antihypertensive drug prescription.
Also, GPs are incited to explain the lab tests planned for
the patient follow-up and to present to the patient the
open text box for patient questions in the care plan.
Once the booklet has been presented to the patient in
this manner, GPs must again remind the patient of the
main value of the booklet and describe the content of
the ADE report form. Our hypothesis is that the
InPAct booklet should facilitate the interaction be-
tween GPs, who are primary healthcare professionals,
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by patients.
Comparator
The care management of antihypertensive-treated pa-
tients carried out by GPs belonging to the control group
(i.e., prior to InPAct program implementation in their
cluster) will be identical to the usual practice. All out-
comes will be assessed three months after patient enrol-
ment, partly by the GP and partly through a phone
survey of the patient. All outcomes will be identically
collected in both control and intervention groups
(Figure 2).
Outcome measurement
The primary outcome of the InPAct study is the
reporting of ADEs by antihypertensive-treated patients
to their GP during the three-month period following
enrolment. Patient reporting was defined as all patient
reports to the GP of a medical issue for which the pa-
tient suggested a drug to be the cause. The secondary
outcomes are: ADE-associated medical complications
presented by antihypertensive-treated patients (e.g., ortho-
static hypotension, falls, renal failure, hydroelectrolytic
disorders, dehydration, confusion syndrome, heart
rhythm disorder, or hospitalisation); ADEs presented
by antihypertensive-treated patients (reported or not); sit-
uations presenting a risk of ADEs for antihypertensive-
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Figure 2 Diagram of the management of patients included in the InPGP, following an ADE; a patient knowledge evaluation (on
hypertension and corresponding care, on benefits, risks
and management of risk associated with drug prescrip-
tions); and an evaluation of patient satisfaction.
Data collection
When a patient is recruited for the study, the GP will
need to enter the patient’s clinical data and prescription
into an electronic case report form (e-CRF) (Figure 2).
After three months of patient follow-up, the GP will
have to collect data on ADE occurrence, patient ADE
reporting and prescription modifications, for entry into
the e-CRF. Also after three months of patient follow-up,
clinical research associates are to interview patients
using a standardised phone questionnaire dealing with
ADE occurrence, situations presenting a risk of ADEs,
ADEs that occurred without being detected by GPs, and
patient skills and satisfaction concerning their medical
care. The associates will have to enter the corresponding
data into the e-CRF and will have to provide a detailed
explanation of all drug prescriptions made by the GP.
Sample size
Sample size calculations were carried out using the
method implemented by Hussey and Hughes [20]. In
our study, the number of clusters was fixed at eight, and
the number of time periods was fixed at five. The
expected effect of the intervention is an absolute in-
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3% in the group without intervention to 7.5% in the
group with intervention. The clustering induces an in-
crease in the variance of the outcome criterion, due to
inter-cluster heterogeneity; this increase is quantified by
the inter-cluster coefficient of variation. For a given
number of patients per cluster, the power of the study
was calculated for different coefficients of variation be-
tween 0.1 and 0.5, which corresponds to the range of
values usually observed. The inclusion of 240 patients
per time period (30 patients per cluster) leads to a power
greater than 80% regardless of the coefficient of vari-
ation (Table 1). The type I error was fixed at 5% for a bi-
lateral test. In the context of the InPAct study, for
logistical reasons and to avoid the risks of inter-cluster
contamination and clusters with no inclusion, it was
preferable to limit the number of GP clusters. With a
classic CRCT parallel group design, the number of pa-
tients to include would have to be at least 6,000 to main-
tain a statistical power of 80% with 12 clusters (under 12
clusters it is impossible to reach a statistical power of
80%, regardless of the number of patients), but with our
choice of stepped wedge design, the patient number de-
creases to 1,200 for eight clusters with a statistical power
of 80%.
The expected percentage of hypertensive patients
reporting at least one ADE is determined as follows: the
proportion of patients with ADEs within the first three
months of antihypertensive treatment has been esti-
mated at 12.6% in Gandhi et al. [2]; and the frequency of
ADEs reported by patients has been estimated to be four
times lower than that reported by health professionals
and seven times lower than that reported by GPs [7,9].
Our hypothesis is that when four patients experience an
ADE, only one reports it. We have therefore estimated
that prior to the implementation of the InPAct program,
3% of antihypertensive-treated patients would report an
ADE.
Randomisation
Before the beginning of the implementation phase, clus-
ters were randomly allocated a time when they are to beTable 1 Statistical power calculated from the coefficient
of variation and number of patients per time period






0 0.80 0.85 0.89
0.1 0.80 0.84 0.89
0.2 0.78 0.83 0.87
0.3 0.76 0.81 0.85
0.4 0.74 0.78 0.83
0.5 0.72 0.76 0.81given the intervention. In agreement with the CONSORT
statement extended to cluster randomised trials, the team
of statisticians, which was blinded to the identity of the
clusters, randomised the clusters using computer gener-
ated random numbers [21]. The randomisation sequence
was therefore established before the beginning of program
implementation. Only the research team was aware of the
allocation of all of the clusters. In order to maintain allo-
cation concealment, GPs will be informed of their alloca-
tion time only in the month prior to the date of
implementation in their cluster. This one-month delay is
necessary for the organisation of their training for the
InPAct program.
It is impossible to blind patients and GP participants
for the intervention, due to the nature of the interven-
tion, i.e., training GPs in the distribution of a booklet to
patients. Outcome assessment will, however, be essen-
tially blinded. Indeed, most of the data are collected in a
blinded fashion by clinical research associates, whereas
the only non-blinded medical data will be those col-
lected by the GPs.
Statistical analysis
The quantitative characteristics of the patients included
during the control and intervention periods will be de-
scribed either by using the mean and the standard devi-
ation, or by using the quartiles and the minimum and
maximum values, depending on the shape of the distri-
bution. The qualitative characteristics of the patients will
be described using the absolute and relative frequencies
in the different categories. The comparisons between the
two groups will be carried out using a student-t test or a
non-parametric test for the quantitative characteristics
and a chi-squared test or a Fisher’s exact test for the
qualitative characteristics.
A stepped wedge design is a unidirectional crossover
trial. The particularity of this design, in comparison with
traditional crossover studies, is that the information
allowing quantification and testing of the intervention
effect is present within and between the clusters. As
recommended by Hussey and Hughes [20], the analysis
of the intervention effect on the main outcome will be
carried out using a mixed logistic model with a random
intercept, in order to take into account the within-
cluster correlation, to use both within-cluster and
between-cluster information, and to take into account
any evolution of the intervention effect over time. The
mixed logistic model may be used to analyse a cluster
randomised trial even when the number of clusters is
small, as long as the number of patients per cluster is
greater than approximately 30, which is the case in our
study. Austin showed that the estimation of the regres-
sion coefficient, which quantifies the intervention effect,
preserves good properties in terms of bias and coverage
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subjects per cluster is over 30, and even if the number of
clusters is as few as five [22]. This analysis will be carried
out using the lme4 package of the most recent version
of the R software.
Ethical consideration
GP investigators must recommend that all patients who
are consulting for antihypertensive prescription consider
participating in this study, without conducting any selec-
tion of patients to be approached or not. The participat-
ing patients will give their written informed consent
after being told about the study. Their participation or
refusal will not affect their medical and nursing care.
Trial status
The InPAct study is funded by the French National Pro-
gram for Hospital Clinical Research. The study protocol
was reviewed and approved on June 28, 2011, by the
Hospital Ethics Committee. All procedures are in ac-
cordance with the Declaration of Helsinki. The InPAct
study has been registered as a clinical trial (Current
Controlled Trials NCT01610817). The enrolment of pa-
tients has begun, but data cleaning or analysis had not
yet begun as of this article’s submission.
Discussion
This article has outlined the design and method of data
collection for the InPAct study, as well as details on the
implementation of the intervention. The aim of this
study is to evaluate how effectively the InPAct program
encourages patient-GP interaction and improves patient-
initiated ADE reporting. This is the first randomised
controlled study that combines a patient education pro-
gram and a patient reporting system for ADEs with the
aim of improving patient safety in primary care.
Originality of the InPAct program
The InPAct program is a patient safety and patient edu-
cation intervention that has been developed and evalu-
ated through successive qualitative and quantitative
studies as recommended by the Medical Research Coun-
cil [23]. The implementation of the InPAct program may
increase ADE reporting by patients in general practice.
In order to improve communication, the InPAct pro-
gram will encourage GPs to ask their patients about
their condition, their antihypertensive prescription
drugs, their other healthcare prescriptions, and their ex-
perience with ADEs. The GP will inform the patient
about the benefits and risks of antihypertensive prescrip-
tion drugs. The patient will be encouraged to participate
actively in his care by writing a care plan and in his own
safety by detecting and describing ADEs using the report
form included in the InPAct booklet. The GP willanalyse patient reports to establish what role, if any, a
particular drug may have played in the onset of an ADE.
It is expected that the detection of ADEs and their de-
scription in report forms by patients will promote the
implementation of corrective and preventive actions to
reduce the occurrence of ADEs and their complications
in general practice. Interventions to improve drug man-
agement in general practice have already been tested.
Weingart et al. have shown in an observational study
that the reception of an automatic email with informa-
tion about ADE interactions and allergies within the first
10 days of a new prescription can improve communica-
tion between a patient and his GP [24]. Roughead et al.
have demonstrated that educational materials for GPs
and patients can improve the verification of the prescrip-
tion by patients at home [25]. Fick et al. have shown that
an educational booklet with a list of inappropriate medi-
cations for the elderly can improve a review of prescrip-
tions by GPs [26]. In these general practice intervention
studies, however, patients were not encouraged to par-
ticipate actively in their care, and professional practice
was assessed instead of patient outcomes.
A program combining both oral and written informa-
tion can foster improved communication between a pa-
tient and his GP. Such a program can also provide
patients with enhanced skills for participating in their
own care. It has been shown that information leaflets
can improve antibiotic use for respiratory tract infection
care management in general practice [27], and that self-
management leaflets and booklets for minor illness can
reduce the number of inappropriate consultations [28].
Moreover, educational leaflets and questions on know-
ledge about contraception [29] or hypertension [30] can
improve not only patient knowledge, but also patient
compliance. Finally, we have identified only one study
that has demonstrated the effectiveness of patient educa-
tion in reducing the frequency of ADE occurrence [31].
We have not identified other educational patient pro-
grams that have shown a statistically significant im-
provement in ADE prevention. None of these studies
featured a combination of a patient education program
and a patient reporting system for ADEs that aimed to
prevent ADEs and reduce their associated complications.
Advantages of the stepped wedge design in the
particular context of a study in general practice
The stepped wedge trial design used in this study is a
particular form of cluster randomised controlled design
that is especially useful for the evaluation of patient
safety programs in general practice. Findings from such
a study design have been shown to generate sound sci-
entific evidence and may make it easier to implement
complex health interventions. The CRCT stepped wedge
design can prove the effectiveness of an intervention
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in particular in the case of routine implementation. This
design is particularly relevant when for logistical, prac-
tical or financial reasons, it is difficult to deliver the
intervention simultaneously to all of the clusters [15-17].
First, in the InPAct study, it was inappropriate to use
individual randomisation of patients, because GPs must
be trained in the intervention (InPAct program). We
therefore used cluster randomisation of GPs belonging
to the same office or network of knowledge or care in
order to avoid contamination bias. Second, it was diffi-
cult to use a parallel design as in a classic CRCT. Indeed,
for logistical reasons, and because the workload and
availability of GPs can be adversely affected at certain
times of the year (due to winter epidemics, seasonal al-
lergies, or high demand for back-to-school medical cer-
tificates in September), it was difficult to implement the
program to all GPs simultaneously in the InPAct study.
One advantage of the stepped wedge design is that the
program will be introduced to GPs sequentially in the
order assigned by randomisation. So, only some GPs
must be trained simultaneously in the presentation of
the booklet, over a particular time period. Third, since
we obtained no arguments in favour of an adverse effect
of the InPAct program during the pilot study [18], and
since all GPs will eventually receive the intervention
(which is a characteristic of the stepped wedge design
versus a classic CRCT design), GPs are motivated to
continue their participation until study’s end.
There are also statistical advantages to choosing a
CRCT stepped wedge trial. First of all, GPs are their own
controls in both control and intervention groups. This
improves comparability in both groups. The CRCT
stepped wedge design may also require fewer clusters
than a CRCT parallel group design to ensure similar
group comparability, in terms of population characteris-
tics. This design therefore increases statistical power
compared to parallel group design, because the program
effect is estimated not only by between-cluster compari-
sons but also by within-cluster comparisons. This sug-
gests that the use of a stepped wedge design should
decrease patient sample size, compared to a classic
CRCT parallel group design [17,20,32]. For the InPAct
study, the number of patients to be included (1,200) was
calculated to be strongly reduced with a stepped wedge
design versus a classic CRCT design, in order to main-
tain the statistical power of 80% and a cluster number of
eight. Additionally, the effects of time can be included in
our choice of statistical model, which allows temporal
changes in the effectiveness of the program to be consid-
ered [16,17,20]. Indeed, the opportunities arising from
modelling the effects of time can be illustrated by con-
sidering the stepped wedge design as a multiple-arm
parallel design, in which the research aims not only toassess intervention effects, but also to determine
whether time of intervention affects the effectiveness of
the intervention. Such time effects can include seasonal
variations both in GP practice and in the reporting, oc-
currence and progression of ADEs. In general practice,
the seasonal variability in the workload of GPs may
negatively affect both their availability for providing
health information and the effectiveness of the interven-
tion for the patient. The behaviour of both GPs and pa-
tients could also be influenced by external factors that
are independent of the study, such as a public campaign
about a reporting system for ADEs. For the patients, di-
uretic antihypertensive-associated ADEs such as dehy-
dration may be more serious in summer due to high
temperatures. Even if including time as a random effect
could be an advantage of the stepped wedge design,
Hussey and Hughes have suggested that a relatively
complex model might be required to take into account
the time effect [20].
Finally, the InPAct study will provide additional know-
ledge about the effects of both an interactive program
for GPs and patients, and an ADE reporting system for
patients. If the InPAct program is found to be effective
in increasing ADE reporting by hypertensive patients
and in implementing corrective and preventive actions
for improving patient safety in general practice, then this
program could be implemented in other regions. Indeed,
another advantage of the stepped wedge design is its fac-
ulty to test the feasibility of implementing an intervention
in a certain number of regions prior to its generalisation.
Moreover, other similar programs, using the same levers,
could be implemented for other commonly prescribed
drugs such as anticoagulants, psychotropics, analgesics, or
antibiotics in primary care.
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